Pharma BD Deal Intelligence
Merck pays $625M to settle patent battle with Bristol-Myers Squibb and Ono over PD-1 antibody Keytruda intellectual property rights
Merck announces settlement and license agreement resolving Keytruda pembrolizumab patent litigation with BMS and Ono for $625 million
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Merck settled patent litigation with BMS and Ono Pharmaceutical over Keytruda (pembrolizumab) by paying $625M upfront plus ongoing royalties on worldwide Keytruda sales. The settlement resolved disputes over anti-PD-1 antibody intellectual property, enabling Merck to continue marketing Keytruda, which became the world's top-selling drug exceeding $25B in annual sales.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Bristol-Myers Squibb Company (this deal) | 2017 | $625M | 74 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2017 deals · Merck & Co. Inc. deals · Oncology deals